Search Results

You are looking at 201 - 210 of 441 items for :

  • "Adjuvant therapy" x
  • Refine by Access: All x
Clear All
Full access

Deirdre R. Pachman, Kathryn Ruddy, Lindsey R. Sangaralingham, Axel Grothey, Nilay D. Shah, Andreas S. Beutler, Joleen M. Hubbard, and Charles L. Loprinzi

across the world, including an adjuvant therapy trial (N04C7) that had accrued approximately 100 patients. However, a subsequent review of the data monitoring committee report showed that it was aberrant, and a subsequent Letter to the Editor in JCO

Full access

Laura Spring, Rachel Greenup, Andrzej Niemierko, Lidia Schapira, Stephanie Haddad, Rachel Jimenez, Suzanne Coopey, Alphonse Taghian, Kevin S. Hughes, Steven J. Isakoff, Leif W. Ellisen, Barbara L. Smith, Michelle Specht, Beverly Moy, and Aditya Bardia

counterparts, which might be due to aggressive tumor biology and lower efficacy of adjuvant therapy, including endocrine therapy for HR-positive breast cancer in young women. For example, among patients with HR-positive disease, there are data in a Korean

Full access

Aaron M. Cheng and Douglas E. Wood

understaged may not receive the appropriate adjuvant therapy, and this is likely to result in survival differences now that adjuvant therapy has become standard of care for resected stage II or greater lung cancer. The NCCN Guidelines for Non–Small Cell Lung

Full access

Venkata K. Pokuri, Mihai Merzianu, Shipra Gandhi, Junaid Baqai, Thom R. Loree, and Seema Bhat

poor predictors of outcome. The role of adjuvant therapy remains unclear. Chemotherapy options for metastatic disease are controversial. The authors have disclosed that they have no financial interests, arrangements, affiliations, or

Full access

Robert J. Motzer, Eric Jonasch, Neeraj Agarwal, Clair Beard, Sam Bhayani, Graeme B. Bolger, Sam S. Chang, Toni K. Choueiri, Brian A. Costello, Ithaar H. Derweesh, Shilpa Gupta, Steven L. Hancock, Jenny J. Kim, Timothy M. Kuzel, Elaine T. Lam, Clayton Lau, Ellis G. Levine, Daniel W. Lin, M. Dror Michaelson, Thomas Olencki, Roberto Pili, Elizabeth R. Plimack, Edward N. Rampersaud, Bruce G. Redman, Charles J. Ryan, Joel Sheinfeld, Brian Shuch, Kanishka Sircar, Brad Somer, Richard B. Wilder, Mary Dwyer, and Rashmi Kumar

these with patients and families and pick the best approach on a case-by-case basis. Adjuvant Therapy: Oliver et al 35 reported on the results of a trial that randomized 1477 patients with stage 1 testicular cancer to undergo either radiotherapy or

Full access

Emily Chan, Paul E. Wise, and A. Bapsi Chakravarthy

excision and no adjuvant therapy . J Gastrointest Surg 1999 ; 3 : 642 – 647 . 16 Guillem JG Diaz-Gonzalez JA Minsky BD . cT3N0 rectal cancer: potential overtreatment with preoperative chemoradiotherapy is warranted . J Clin Oncol 2008 ; 26

Full access

Louis Burt Nabors, Mario Ammirati, Philip J. Bierman, Henry Brem, Nicholas Butowski, Marc C. Chamberlain, Lisa M. DeAngelis, Robert A. Fenstermaker, Allan Friedman, Mark R. Gilbert, Deneen Hesser, Matthias Holdhoff, Larry Junck, Ronald Lawson, Jay S. Loeffler, Moshe H. Maor, Paul L. Moots, Tara Morrison, Maciej M. Mrugala, Herbert B. Newton, Jana Portnow, Jeffrey J. Raizer, Lawrence Recht, Dennis C. Shrieve, Allen K. Sills Jr, David Tran, Nam Tran, Frank D. Vrionis, Patrick Y. Wen, Nicole McMillian, and Maria Ho

: Chemotherapy is not a traditional mainstay of upfront treatment for low-grade gliomas. Some data support temozolomide as adjuvant therapy, and it is included as a category 2B recommendation based on nonuniform panel consensus. A phase II trial of temozolomide

Full access

Rahel Demisse, Neha Damle, Edward Kim, Jun Gong, Marwan Fakih, Cathy Eng, Leslie Oesterich, Madison McKenny, Jingran Ji, James Liu, Ryan Louie, Kit Tam, Sepideh Gholami, Wissam Halabi, Arta Monjazeb, Farshid Dayyani, and May Cho

fluorouracil-based adjuvant therapy in colon cancer . J Clin Oncol 2010 ; 28 : 3219 – 3226 . 20498393 10.1200/JCO.2009.27.1825 13. Salem ME , Hartley M , Unger K , . Neoadjuvant combined-modality therapy for locally advanced rectal cancer and its

Full access

Presenters: Douglas B. Johnson, Susan M. Swetter, April K.S. Salama, and Evan Wuthrick

number of unnecessary SLNBs, and inform decisions on imaging and adjuvant therapy, she explained, but there are still several unknowns. Nevertheless, experts estimate that up to 10% of all invasive melanomas are being GEP-tested with commercially

Full access

Presenters: Dara L. Aisner and Gregory J. Riely

NCCN Guidelines now list osimertinib as an option for adjuvant therapy in patients with resectable stage IIB–IIIA or high-risk stage IB–IIA NSCLC harboring EGFR mutations who received previous adjuvant chemotherapy or are ineligible to receive